Biotech Values

[DewDiligence]

Re: ABT’s business in China

Has ABT talked much about expectations for growth in China over the coming years?

Yes—the subject comes up on every ABT CC. The growth expectations for China vary by business segment, of which there are four (#msg-130598839).

ABT sees double-digit growth in pharma (branded generics); mid-to-high single-digit growth in medical devices and diagnostics; and low-single-digit growth in nutrition products. ABT says the comparatively slow growth in nutrition is due to recent regulatory changes and is expected to be temporary; when the dust settles, ABT expects a return to high-single-digit growth in this segment.